Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Mechanism of impaired glucose...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

Bibliographic Details
Published in:Haematologica
Main Authors: Zdenek Racil, Filip Razga, Jana Drapalova, Lucie Buresova, Daniela Zackova, Martina Palackova, Lukas Semerad, Ludmila Malaskova, Martin Haluzik, Jiri Mayer
Format: Article
Language:English
Published: Ferrata Storti Foundation 2013-10-01
Online Access:https://haematologica.org/article/view/6819
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/6819

Similar Items

  • Chronic myelogenous leukemia on target
    by: Veronika Némethová, et al.
    Published: (2018-07-01)
  • Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
    by: Harnicar S, et al.
    Published: (2014-08-01)
  • Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients
    by: Gaëlle Fossard, et al.
    Published: (2016-03-01)
  • The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients
    by: Petra Belohlavkova, et al.
    Published: (2018-02-01)
  • Nilotinib cause moyamoya disease in the treatment of chronic myelogenous leukemia during chronic phase: A case report
    by: Jin-ping Liang, et al.
    Published: (2023-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs